Compare
Pasithea Therapeutics Corp. vs ProPhase Labs, Inc. vs Palvella Therapeutics, Inc. vs ALX Oncology Holdings Inc
| Latest fiscal year | Pasithea Therapeutics Corp. KTTA | ProPhase Labs, Inc. PRPH | Palvella Therapeutics, Inc. PVLA | ALX Oncology Holdings Inc ALXO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $4.34M | n/a | n/a |
| Revenue growth (YoY) | n/a | -35.8% | n/a | n/a |
| Gross margin | n/a | 31.9% | n/a | n/a |
| Operating margin | n/a | -415.4% | n/a | n/a |
| Net margin | n/a | -339.3% | n/a | n/a |
| Net income | -$20.43M | -$14.74M | -$41.72M | -$101.69M |
| EPS (Diluted) | -$2.91 | -$1.74 | -$3.71 | -$1.90 |
| Operating cash flow | -$15.21M | -$8.34M | -$25.01M | -$84.14M |
| Free cash flow | n/a | -$8.34M | n/a | -$84.35M |
| Cash & equivalents | $55.16M | $90.0K | $57.98M | $16.37M |
| Total assets | $60.24M | $59.87M | $59.56M | $59.05M |
| Total liabilities | $5.02M | $56.36M | $31.58M | $33.06M |
| Shareholders' equity | $55.22M | $3.51M | $27.98M | $25.98M |
| Return on year-end equity | -37.0% | -420.3% | -149.1% | -391.4% |
| Shares outstanding | 23.09M | 8.97M | 12.38M | 54.39M |
Revenue, most recent five fiscal years
| Fiscal year | Pasithea Therapeutics Corp. | ProPhase Labs, Inc. | Palvella Therapeutics, Inc. | ALX Oncology Holdings Inc |
|---|---|---|---|---|
| Latest | $486.6K Ended 2022-12-31 | $4.34M Ended 2025-12-31 | $42.81M Ended 2023-12-31 | $0 Ended 2022-12-31 |
| 1 year earlier | $15.1K Ended 2021-12-31 | $6.77M Ended 2024-12-31 | $25.90M Ended 2022-12-31 | $0 Ended 2021-12-31 |
| 2 years earlier | n/a | $34.98M Ended 2023-12-31 | $31.42M Ended 2021-12-31 | $1.18M Ended 2020-12-31 |
| 3 years earlier | n/a | $122.65M Ended 2022-12-31 | $29.32M Ended 2020-12-31 | $4.80M Ended 2019-12-31 |
| 4 years earlier | n/a | $79.04M Ended 2021-12-31 | $46.28M Ended 2019-12-31 | $2.07M Ended 2018-12-31 |